| __timestamp | Sarepta Therapeutics, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 49315000 | 1802274 |
| Thursday, January 1, 2015 | 75043000 | 2512761 |
| Friday, January 1, 2016 | 83749000 | 2894488 |
| Sunday, January 1, 2017 | 122682000 | 8096274 |
| Monday, January 1, 2018 | 207761000 | 7985229 |
| Tuesday, January 1, 2019 | 284812000 | 8994597 |
| Wednesday, January 1, 2020 | 317875000 | 29772000 |
| Friday, January 1, 2021 | 282660000 | 33907000 |
| Saturday, January 1, 2022 | 451421000 | 26579000 |
| Sunday, January 1, 2023 | 481871000 | 49868547 |
Cracking the code
In the competitive world of biotechnology, managing operational expenses is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and Verona Pharma plc from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by nearly 900%, reflecting its aggressive growth strategy. In contrast, Verona Pharma's expenses increased by approximately 2,700%, albeit from a much smaller base, indicating its expansion efforts.
Sarepta's expenses peaked in 2023, reaching nearly $482 million, a testament to its significant market presence. Meanwhile, Verona Pharma's expenses, though much lower, showed a consistent upward trend, peaking at nearly $50 million in 2023. This divergence highlights the different scales and strategies of these companies. Investors and industry watchers should note these trends as they reflect each company's operational focus and market positioning.
Cost Management Insights: SG&A Expenses for AbbVie Inc. and Sarepta Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Sarepta Therapeutics, Inc.
Selling, General, and Administrative Costs: argenx SE vs Verona Pharma plc
Neurocrine Biosciences, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Incyte Corporation vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
Comparing SG&A Expenses: Sarepta Therapeutics, Inc. vs Wave Life Sciences Ltd. Trends and Insights
Selling, General, and Administrative Costs: Jazz Pharmaceuticals plc vs Verona Pharma plc
Operational Costs Compared: SG&A Analysis of TG Therapeutics, Inc. and Verona Pharma plc
Who Optimizes SG&A Costs Better? Verona Pharma plc or Amneal Pharmaceuticals, Inc.